Patient Characteristics, Treatment and Outcome in Non-Ischemic vs. Ischemic Cardiogenic Shock

Benedikt Schrage1,2, Jessica Weimann1, Salim Dabboura2

  • 1Department of Cardiology, University Heart and Vascular Centre Hamburg, 20251 Hamburg, Germany.

Insights

Non-ischemic cardiogenic shock (CS) affects over half of CS patients and is linked to worse outcomes. This study highlights significant differences in patient profiles and treatments, emphasizing the need for targeted strategies for non-ischemic CS.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Internal Medicine

Background:

  • Non-ischemic cardiogenic shock (CS) is understudied, with limited evidence on its distinct characteristics and outcomes compared to ischemic CS.
  • Understanding these differences is crucial for developing effective management strategies.

Purpose of the Study:

  • To investigate and compare patient demographics, treatment modalities, and clinical outcomes between non-ischemic CS and ischemic CS.
  • To identify factors associated with mortality in non-ischemic CS.

Main Methods:

  • A retrospective analysis of 978 patients with CS admitted between 2009 and 2017.
  • Patients were stratified into non-ischemic and ischemic CS groups based on the presence of acute myocardial infarction.
  • Logistic and Cox regression models were used to analyze associations with mortality.

Main Results:

  • Non-ischemic CS constituted over 50% of cases, with patients being younger, more often female, and presenting with unfavorable hemodynamics.
  • Treatment variations included higher catecholamine use but lower use of extracorporeal membrane oxygenation and mechanical assist devices in non-ischemic CS.
  • Non-ischemic CS was independently associated with a significantly increased risk of 30-day in-hospital mortality (HR 1.14).

Conclusions:

  • Non-ischemic CS presents unique patient characteristics and treatment patterns compared to ischemic CS.
  • Non-ischemic CS is associated with a worse prognosis, underscoring the urgent need for tailored therapeutic interventions.
  • Further research into effective treatment strategies for non-ischemic CS is warranted.

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.4K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
445
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
172
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
350
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
237
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
289